Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines

Item Type:Article
Title:Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines
Creators Name:Ringel, F. and Kaeda, J. and Schwarz, M. and Oberender, C. and Grille, P. and Doerken, B. and Marque, F. and Manley, P.W. and Radimerski, T. and le Coutre, P.
Abstract:Janus kinases are critical components of signaling pathways that regulate hematopoiesis. Mutations of the non-receptor tyrosine kinase JAK2 are found in many BCR-ABL-negative myeloproliferative neoplasms. Preclinical results support that JAK2 inhibitors could show efficacy in treating chronic myeloproliferative neoplasms. JAK2 has also been postulated to play a role in BCR-ABL signal transduction. Therefore, inhibitors of JAK2 kinases are turning into therapeutic strategies for treatment of chronic myelogenous leukemia (CML). In this study, the effects of two novel JAK2 inhibitors, NVP-BSK805 and NVP-BVB808, have been investigated in cell lines expressing either BCR-ABL or mutant JAK2. Possible synergies between NVP-BSK805/NVP-BVB808 and the kinase inhibitors imatinib and nilotinib were assessed. Proliferation and apoptosis tests with both substances showed response in the following cell lines: CHRF-288-11, SET-2 and UKE-1. All BCR-ABL-positive cell lines showed some reduction in proliferation, but with half-maximal growth-inhibitory values >1 {mu}M. Combination of the JAK2 inhibitors with imatinib and nilotinib showed no significant additive or synergistic effects, although all BCR-ABL-positive cell lines responded well to both CML therapeutic agents. Interestingly, it seemed that the combination of imatinib with NVP-BSK805 had a protective effect on the cells. Combination treatment with nilotinib did not show this effect.
Keywords:BCR-ABL, Chronic Myeloproliferative Neoplasia, JAK2 Mutation, Tyrosine Kinase Inhibitors
Source:Acta Haematologica
ISSN:0001-5792
Publisher:Karger (Switzerland)
Volume:132
Number:1
Page Range:75-86
Date:31 January 2014
Official Publication:https://doi.org/10.1159/000356784
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library